Nivolumab is an intravenous drug under development for the management of advanced (Stage IV) NSCLC. The drug acts on specific proteins (receptors) on immune cells, allowing the defence system of the body to decrease the growth of cancer cells. If licensed, Nivolumab in combination with the current standard of care (platinum doublet chemotherapy) may offer an additional treatment option for patients with advanced NSCLC who currently have failed to respond to standard of care chemotherapy alone.
ALXN1210 is an antibody under development that prevents the destruction of red blood cells (RBCs). The drug is administered by intravenous injection that requires fewer dosing regimen compared to current treatment option. If ALXN1210 is licensed for use in the UK, it could represent an additional treatment option for patients with paroxysmal nocturnal haemoglobinuria.